HER2-negative Breast Cancer – A Pathologist’s Perspective
As the treatment landscape for breast cancer evolves, so too must the interpretation of pathology results. For HER2-negative breast cancer (IHC 0, 1+, and 2+ [ISH-negative]), interpretation can have a significant impact on treatment decisions and patient prognosis. Professor Johan Hartman shares his experience and insights.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
